Summanen Jari, Yrjönen Teijo, Christiansen Leena, Mervaala Eero, Vaskonen Timo, Lassila Markus, Ahotupa Markku, Yliruusi Jouko, Karppanen Heikki, Hiltunen Raimo
Division of Pharmacognosy, Department of Pharmacy, University of Helsinki, PO Box 56, FIN-00014 Helsinki, Finland.
J Pharm Pharmacol. 2003 Dec;55(12):1673-9. doi: 10.1211/0022357022331.
Because dietary fat appears to be an effective vehicle for dispensing plant sterols into the diet, a special plant-sterol-containing ingredient has recently been developed. This ingredient is a plant sterol suspension in oil in which the sterols are in microcrystalline form. The objective of the present study was to analyse the cholesterol-lowering effects and safety of two different plant sterol preparations, an orally administered microcrystalline plant sterol suspension (MPS) in rapeseed oil and a powdered plant sterol supplement, in obese Zucker rats. Dietary plant sterol supplements (0.5%, w/w) were given concurrently with a high cholesterol diet (HCD, 1% cholesterol and 18% fat, w/w). No significant changes in serum triglyceride, blood glucose, serum glutamate oxaloacetic transaminase and glutamic pyruvic transaminase values or body and liver weights were observed. The powdered plant sterol supplement lowered the serum cholesterol by 25% (P < 0.05) and the MPS diet by 35% (P < 0.001) compared with HCD by the end of the 12-week experiment. Interestingly, the plant sterol supplements also produced a marked reduction in serum ubiquinone levels, suggesting a possible effect on isoprene synthesis. Unlike the powdered plant sterol, both MPS and plain rapeseed oil decreased the serum baseline diene conjugation values, suggesting that they protect against oxidative stress-induced lipid peroxidation in rats. This lipid peroxidation diminishing effect is probably due to some antioxidative components in rapeseed oil. These findings indicate that an unesterified plant sterol, such as the microcrystalline suspension in oil, effectively prevents cholesterol absorption in obese Zucker rats.
由于膳食脂肪似乎是将植物甾醇添加到饮食中的一种有效载体,最近已开发出一种特殊的含植物甾醇成分。该成分是一种油中的植物甾醇悬浮液,其中甾醇呈微晶形式。本研究的目的是分析两种不同植物甾醇制剂(一种口服的菜籽油微晶植物甾醇悬浮液(MPS)和一种植物甾醇粉末补充剂)对肥胖Zucker大鼠的降胆固醇作用和安全性。膳食植物甾醇补充剂(0.5%,w/w)与高胆固醇饮食(HCD,1%胆固醇和18%脂肪,w/w)同时给予。未观察到血清甘油三酯、血糖、血清谷氨酸草酰乙酸转氨酶和谷氨酸丙酮酸转氨酶值或体重及肝脏重量有显著变化。在为期12周的实验结束时,与HCD相比,植物甾醇粉末补充剂使血清胆固醇降低了25%(P<0.05),MPS饮食使血清胆固醇降低了35%(P<0.001)。有趣的是,植物甾醇补充剂还使血清泛醌水平显著降低,表明可能对异戊二烯合成有影响。与植物甾醇粉末不同,MPS和纯菜籽油均降低了血清基线二烯共轭值,表明它们可预防大鼠氧化应激诱导的脂质过氧化。这种脂质过氧化减弱作用可能归因于菜籽油中的一些抗氧化成分。这些发现表明,未酯化的植物甾醇,如油中的微晶悬浮液,可有效防止肥胖Zucker大鼠吸收胆固醇。